vTv Therapeutics Inc. (VTVT) stock
VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3062% below fair value
$17.29−0.40 (-2.26%)
Close on Nov 17, 2026Market cap $68.37MP/E –Yield –
vTv Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
vTv Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $28.68M, up 131.4% year over year. For fiscal 2025 it was $17.86M, up 54.7% from the year before. Over ten years it grew -4.1% a year on average. The highest annual figure on record is $44.95M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.86M | +54.7% |
| FY2024 | Dec 31, 2024 | $11.55M | -15.1% |
| FY2023 | Dec 31, 2023 | $13.60M | +10.0% |
| FY2022 | Dec 31, 2022 | $12.36M | -7.3% |
| FY2021 | Dec 31, 2021 | $13.32M | +21.0% |
| FY2020 | Dec 31, 2020 | $11.02M | -27.1% |
| FY2019 | Dec 31, 2019 | $15.12M | -34.4% |
| FY2018 | Dec 31, 2018 | $23.04M | -41.9% |
| FY2017 | Dec 31, 2017 | $39.64M | -11.8% |
| FY2016 | Dec 31, 2016 | $44.95M | +65.0% |
| FY2015 | Dec 31, 2015 | $27.24M | +56.7% |
| FY2014 | Dec 31, 2014 | $17.38M | -22.0% |
| FY2013 | Dec 31, 2013 | $22.29M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.77M | +113.7% |
| Q1 FY2026 | Mar 31, 2026 | $8.98M | +217.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.91M | +74.9% |
| Q3 FY2025 | Sep 30, 2025 | $7.02M | +117.7% |
| Q2 FY2025 | Jun 30, 2025 | $4.10M | +19.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.83M | +6.8% |
| Q4 FY2024 | Dec 31, 2024 | $2.23M | +4.5% |
| Q3 FY2024 | Sep 30, 2024 | $3.22M | +14.2% |
| Q2 FY2024 | Jun 30, 2024 | $3.44M | -26.7% |
| Q1 FY2024 | Mar 31, 2024 | $2.65M | -32.8% |
| Q4 FY2023 | Dec 31, 2023 | $2.14M | -46.1% |
| Q3 FY2023 | Sep 30, 2023 | $2.82M | -7.6% |
| Q2 FY2023 | Jun 30, 2023 | $4.69M | +112.7% |
| Q1 FY2023 | Mar 31, 2023 | $3.94M | +25.8% |
| Q4 FY2022 | Dec 31, 2022 | $3.96M | -26.6% |
| Q3 FY2022 | Sep 30, 2022 | $3.06M | +28.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.21M | -9.5% |
| Q1 FY2022 | Mar 31, 2022 | $3.13M | +1.0% |
| Q4 FY2021 | Dec 31, 2021 | $5.40M | +113.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.38M | +34.7% |
| Q2 FY2021 | Jun 30, 2021 | $2.44M | -2.9% |
| Q1 FY2021 | Mar 31, 2021 | $3.10M | -26.2% |
| Q4 FY2020 | Dec 31, 2020 | $2.53M | -42.5% |
| Q3 FY2020 | Sep 30, 2020 | $1.77M | -51.7% |
| Q2 FY2020 | Jun 30, 2020 | $2.51M | -40.7% |
| Q1 FY2020 | Mar 31, 2020 | $4.20M | +49.0% |
| Q4 FY2019 | Dec 31, 2019 | $4.41M | +57.4% |
| Q3 FY2019 | Sep 30, 2019 | $3.66M | +35.8% |
| Q2 FY2019 | Jun 30, 2019 | $4.23M | -50.8% |
| Q1 FY2019 | Mar 31, 2019 | $2.82M | -68.4% |
| Q4 FY2018 | Dec 31, 2018 | $2.80M | -72.2% |
| Q3 FY2018 | Sep 30, 2018 | $2.70M | -70.0% |
| Q2 FY2018 | Jun 30, 2018 | $8.59M | -10.7% |
| Q1 FY2018 | Mar 31, 2018 | $8.94M | -18.4% |
| Q4 FY2017 | Dec 31, 2017 | $10.07M | -9.3% |
| Q3 FY2017 | Sep 30, 2017 | $8.99M | -15.5% |
| Q2 FY2017 | Jun 30, 2017 | $9.62M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.96M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.10M | – |
| Q3 FY2016 | Sep 30, 2016 | $10.64M | – |
See a number that looks wrong?